SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Segment reporting
Number of reportable segments | segment	2
Revenue recognition	$ 106,786	$ 64,477
Depreciation and amortization	14,700	14,557
Corporate and other unallocated expenses	36,468	28,817
Total operating income (loss)	9,895	(19,195)
Interest expense, net	(7,696)	(6,613)
Other expense, net	(34)	(89)
Income (Loss) Before Income Tax (Provision) Benefit	2,165	(25,897)
Operating segments | Generics, Established Brands, and Other
Segment reporting
Revenue recognition	90,456	63,185
EBITDA	38,828	14,531
Operating segments | Rare Disease
Segment reporting
Revenue recognition	16,330	1,292
EBITDA	(1,251)	(10,448)
Unallocated expenses
Segment reporting
Depreciation and amortization	(14,700)	(14,557)
Corporate and other unallocated expenses	(12,982)	(8,721)
Total operating income (loss)	9,895	(19,195)
Interest expense, net	(7,696)	(6,613)
Other expense, net	$ (34)	$ (89)